Zoloft vs. Lexapro: Which Antidepressant is Right for You?
Author:
Blossom Editorial
Zoloft (sertraline) and Lexapro (escitalopram) are two of the most widely prescribed antidepressants in the United States. Both belong to a class of medications called selective serotonin reuptake inhibitors (SSRIs), which work by increasing the availability of serotonin in the brain and are associated with longer-term changes in receptor sensitivity and neural signalling.
While they share a similar mechanism, they differ in their approved uses, dosing ranges, side effect profiles, drug interaction potential, and how they work in special populations like older adults and adolescents.
Choosing between them is rarely straightforward. For some people, either medication could work well. But for others, one is clearly the better fit based on their diagnosis, other medications, and medical history. This guide covers what the research says about Zoloft vs. Lexapro across effectiveness, tolerability, dosing, and who could benefit most from each.
Key Takeaways
Both Zoloft and Lexapro are effective first-line SSRIs used to treat depression. Research suggests Lexapro may have a slight edge in tolerability for some people, while Zoloft has FDA approval for more conditions, including PTSD, OCD, social anxiety disorder (SAD), and PMDD. Lexapro is FDA-approved to treat both depression and generalized anxiety disorder (GAD) in adults and children.
Zoloft has a wider dosing range (50 to 200 mg) and more drug interaction potential than Lexapro, which can matter if you take other medications. Lexapro's simpler pharmacology often makes it a preferred starting point.
The best choice depends on your specific diagnosis, medical history, and how your body responds. Most people need a trial period of 4 to 8 weeks to assess whether a medication is working at a therapeutic dose.
What are Zoloft (Sertraline) and Lexapro (Escitalopram)?
Sertraline was first approved by the FDA in 1991 and is sold under the brand name Zoloft. Escitalopram, under the brand name Lexapro, received FDA approval in 2002. Today, both are available as affordable generics, making them among the most accessible prescription antidepressants.
According to the National Institute of Mental Health, SSRIs are considered first-line treatments for depression and anxiety disorders because of their established safety record and decades of clinical evidence.
As SSRIs, both medications inhibit the reabsorption of serotonin in the presynaptic neurons in the brain, leaving more serotonin available between nerve cells. The increase in serotonin levels increases the activity at serotonin receptor sites, which is thought to improve mood, reduce anxiety, and stabilize emotional regulation.
While Zoloft is also known to inhibit dopamine reuptake mildly, which may contribute to its therapeutic effects, Lexapro is selective towards the serotonin system.
Lexapro (escitalopram) is the active form of Celexa (citalopram). It was developed as a more selective and refined version, which is part of why it tends to have fewer drug interactions and a cleaner side effect profile than many older SSRIs. Lexapro may have a faster onset of action and overall greater effect in reducing anxiety and depression symptoms, compared to Celexa. However, Lexapro costs more than Celexa.
FDA-Approved Uses
Zoloft (Sertraline)
Zoloft has one of the broadest approval profiles among SSRIs, making it a versatile first choice when a patient has multiple conditions or a complex presentation. It is FDA-approved for:
Major depressive disorder (MDD)
Obsessive-compulsive disorder (OCD) in adults and children aged 6 and older
Panic disorder
Lexapro (Escitalopram)
Lexapro has a narrower set of FDA-approved indications, but is frequently prescribed to treat co-occurring depression and anxiety in adults and children:
Major depressive disorder (MDD) — in adults and adolescents aged 12 and older
Generalized anxiety disorder (GAD) — in adults
Despite having fewer formal approvals, Lexapro is commonly used off-label for social anxiety disorder, panic disorder, OCD, and PTSD. The distinction matters mainly from an insurance coverage and prescribing documentation perspective, not from a clinical effectiveness standpoint, for many of these conditions.
How Do They Compare in Effectiveness?
The most influential comparison of antidepressants came from a 2009 meta-analysis published in The Lancet that evaluated 12 antidepressants across 117 randomized controlled trials. Both sertraline (Zoloft) and escitalopram (Lexapro) performed favorably — escitalopram ranked highest for the combination of efficacy and acceptability, while sertraline was highlighted as the most practical first-choice option for moderate to severe depression when balancing effectiveness, tolerability, and cost.
An 8-week head-to-head comparison study of escitalopram (Lexapro) and sertraline (Zoloft) found no clinically meaningful difference in response between the two. Both produced comparable response rates in patients with major depression, with escitalopram at 75% and sertraline at 70%. Discontinuation rates due to adverse effects were largely similar, at 2% and 4%, respectively, indicating both medications are generally well tolerated.
A more recent network meta-analysis published in The Lancet as a follow-up to the 2009 study compared 21 antidepressants across 522 trials. While escitalopram was among the more effective antidepressants, both escitalopram (Lexapro) and sertraline (Zoloft) had better tolerability with respect to other antidepressants.
For anxiety disorders specifically, both have robust clinical trial data. A review from 2008 found escitalopram effective across GAD, social anxiety, panic disorder, and OCD, while sertraline's evidence spans all of those conditions plus PTSD and PMDD, where it is one of the most studied SSRIs available.
Dosing: Ranges and Flexibility
Dosing differs meaningfully between these two medications and can influence which is more appropriate for a given patient:
Zoloft: typically starts at 50 mg/day for depression, OCD, and PMDD; 25 mg/day is often used for other disorders (PD, PTSD, SAD); maximum dose is 200 mg/day
Lexapro: Starts at 10 mg/day; therapeutic range is 10 to 20 mg/day; maximum dose is 20 mg/day; maximum dose of 10 mg/day is recommended in older adults, partly due to dose-related QT prolongation risk
Zoloft’s wider dosing range gives prescribers more flexibility when a patient needs dose escalation, which can be an advantage in treatment-resistant cases. Lexapro's narrow range simplifies titration — many patients stay at 10 mg indefinitely — and can reduce the complexity of monitoring.
For older adults, Lexapro is often preferred. The recommended maximum dose for people over 65 is 10 mg/day, and its lower drug interaction potential reduces risk in patients who are typically on multiple medications. According to the FDA, dose reduction is recommended for elderly patients and those with liver impairment.
Side Effects: What to Expect
Because both medications are SSRIs working through the same core mechanism, their side effect profiles overlap substantially. Common effects seen with both include nausea (especially in the first two weeks), headache, insomnia or drowsiness, dry mouth, increased sweating, and sexual side effects such as decreased libido or difficulty reaching orgasm.
Both Lexapro (escitalopram) and Zoloft (sertraline) can cause weight changes, though this varies from person to person. Some people gain weight, while others lose weight or stay the same.
Where they diverge is in gastrointestinal tolerability. Zoloft is more likely to cause diarrhea and loose stools in some patients, while Lexapro tends to produce milder GI effects overall. This is one of the reasons Lexapro is often considered among the better-tolerated SSRIs. However, for many people, side effects are mild and often improve after a few weeks as your body adjusts to the medication.
Side Effect | Lexapro | Zoloft |
Nausea | Common | Common |
Headache | Common | Common |
Drowsiness | Common | Common |
Dry mouth | Common | Common |
Sexual side effects | Common | Common |
Weight changes | Possible | Possible |
Diarrhea | Less common | More common |
Dizziness | Common | Common |
Drug Interactions
This is one of the more clinically important differences between the two medications. Zoloft moderately inhibits liver enzymes CYP2D6 and CYP2B6, which are responsible for metabolizing many commonly used medications, including certain blood thinners, beta-blockers, and antiarrhythmics. This can increase the blood levels of these medications and requires careful review of a patient's full medication list.
Lexapro has a relatively low potential for clinically-significant CYP-mediated interactions because it has minimal effect on these enzymes. According to guidance from the FDA drug interaction database, this makes Lexapro easier to use in patients taking multiple medications, particularly older adults on complex regimens.
SSRIs, including Zoloft and Lexapro, carry a risk of bleeding when co-administered with anticoagulants (e.g., warfarin, heparin) or NSAIDs (e.g., aspirin).
MAOIs are a special class of antidepressants that can be extremely dangerous when combined with Zoloft or Lexapro. If you're switching from an MAOI to either of these medications, you must wait at least 14 days. This waiting period allows the MAOI to completely leave your system before starting the new medication.
Both medications carry a risk of serotonin syndrome when combined with other serotonergic drugs, including tramadol, triptans for migraines, certain pain medications, and St. John's Wort. Symptoms of serotonin syndrome include agitation, rapid heart rate, sweating, tremor, and confusion. Always share a full medication and supplement list with your prescriber.
Can You Take Them Together?
No, you should not take Lexapro (escitalopram) and Zoloft (sertraline) together. Taking both medications at the same time increases your risk of serotonin syndrome and other serious side effects.
If your doctor wants to switch you from one medication to another, they'll create a safe plan to make the transition.
Special Populations
Adolescents
Lexapro has a specific FDA approval for depression in adolescents aged 12 and older and for GAD in pediatric patients 7 and above, which makes it one of the FDA-approved options in this age group.
Zoloft OCD approval extends to children as young as 6, making it the preferred SSRI for pediatric OCD. For adolescent depression where OCD is not a concern, either medication may be considered, though escitalopram has a more direct regulatory basis.
Pregnancy and Breastfeeding
Both medications have been studied in pregnancy. However, Zoloft is more preferred due to the large volume of data demonstrating its safety, especially during breastfeeding.
The decision to continue, switch, or discontinue antidepressants during pregnancy requires carefully weighing the risks of untreated mental illness against potential medication exposure. Some SSRIs have been associated with a small risk of neonatal adaptation syndrome or rare complications like persistent pulmonary hypertension of the newborn (PPHN), especially when taken in the third trimester.
However, research shows that untreated depression during pregnancy carries its own risks for both mother and baby, including preterm birth, low birth weight, increased operative delivery, and postpartum depression. This decision should always be made in close partnership with your OB and psychiatrist.
Both medications can pass into breast milk. If you are taking antidepressants while breastfeeding, talk to your provider about the safest approach you can take.
Which One is Right for You?
There is no universally "better" medication — both Zoloft and Lexapro are excellent first-line choices with decades of evidence behind them. The right fit depends on a combination of factors:
Your diagnosis: For PTSD, OCD, or PMDD, Zoloft has FDA approval, whereas Lexapro doesn’t. For coexisting depression and GAD, Lexapro may be a better option.
Other medications: Lexapro's lower drug interaction potential makes it preferable when you are on a complex regimen.
Tolerability history: If GI side effects are a concern, Lexapro's slightly gentler profile may be an advantage.
Dosing flexibility: Zoloft’s wider range may benefit patients who need dose escalation. Lexapro is also available as an oral solution in low dosage (1 mg/ml) to enable a more gradual tapering before discontinuation.
Age: Lexapro may be preferred in some older adults due to lower interaction risk and simpler dosing.
Cost and access: Both are widely available as low-cost generics
If the first medication does not produce adequate results after 6 to 8 weeks at a therapeutic dose, switching to the other is a common and clinically sound next step. Research shows that persistence through medication adjustments — guided by a prescriber — leads to better long-term outcomes than stopping antidepressants prematurely.
Combination treatment, including medication and therapy, is another frequently used approach with better response and lower relapse rates. Warning Information for Zoloft and Lexapro
Before starting treatment, make sure your doctor knows about any health conditions you have. Some conditions might make these medications riskier or require special monitoring. Your doctor can usually still treat your depression or anxiety safely, but they need to know about your health history first.
Tell your doctor if you have:
Bipolar disorder
Bleeding disorders
Liver or kidney disease
History of seizures
Glaucoma
Risk of Suicide
Both medications carry a "black box warning" about increased suicide risk in young people under 25. This increased risk is usually temporary and happens most often during the first few weeks of treatment or when doses are changed.
If you experience these symptoms, contact your doctor immediately. You can also call the National Suicide Prevention Lifeline at 988 if you're having thoughts of hurting yourself.
Medical Disclaimer
This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or medication. If you are experiencing a mental health crisis, contact the 988 Suicide and Crisis Lifeline by calling or texting 988.
Sources
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., et al. (2009). Comparative efficacy and acceptability of 12 new-generation antidepressants: A multiple-treatments meta-analysis. The Lancet, 373(9665), 746–758. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)60046-5/abstract
Sanchez, C., Reines, E. H., & Montgomery, S. A. (2014). A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike?. International clinical psychopharmacology, 29(4), 185–196.
https://pmc.ncbi.nlm.nih.gov/articles/PMC4047306National Institute of Mental Health. (2023, December). Mental health medications. U.S. Department of Health and Human Services, National Institutes of Health. https://www.nimh.nih.gov/health/topics/mental-health-medications
U.S. Food and Drug Administration. (2023). Zoloft (sertraline) tablets and oral solution: Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/019839s108,20990s062lbl.pdf
U.S. Food and Drug Administration. (2024). Lexapro (escitalopram) tablets and oral solution: Prescribing information (Reference ID: 5367836). https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021323s058lbl.pdf
Cavanah, L. R., Ray, P., Goldhirsh, J. L., et al. (2023). Rise of escitalopram and the fall of citalopram. medRxiv : the preprint server for health sciences, 2023.05.07.23289632. https://pmc.ncbi.nlm.nih.gov/articles/PMC10197723
Landy K, Rosani A, Estevez R. Escitalopram. [Updated 2023 Nov 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557734/
Ventura, D., Armstrong, E. P., Skrepnek, G. H., & Haim Erder, M. (2007). Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial. Current medical research and opinion, 23(2), 245–250. https://pubmed.ncbi.nlm.nih.gov/17288677/
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., et al. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. The Lancet, 391(10128), 1357–1366. https://www.thelancet.com/article/S0140-6736(17)32802-7/fulltext
Pelissolo A. (2008). Efficacy and tolerability of escitalopram in anxiety disorders: a review. L'Encephale, 34(4), 400–408. https://pubmed.ncbi.nlm.nih.gov/18922243
U.S. Food and Drug Administration. (n.d.). Drug development and drug interactions: Table of substrates, inhibitors and inducers. https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers
Dunner D. L. (2014). Combining antidepressants. Shanghai archives of psychiatry, 26(6), 363–364. https://pmc.ncbi.nlm.nih.gov/articles/PMC4311111/
Centers for Medicare & Medicaid Services. (2015, October). Antidepressant medications: Use in pediatric patients. U.S. Department of Health and Human Services. https://www.cms.gov/medicare-medicaid-coordination/fraud-prevention/medicaid-integrity-education/pharmacy-education-materials/downloads/ad-pediatric-factsheet11-14.pdf
Jahan, N., Went, T. R., Sultan, W., Sapkota, A., et al (2021). Untreated Depression During Pregnancy and Its Effect on Pregnancy Outcomes: A Systematic Review. Cureus, 13(8), e17251. https://pmc.ncbi.nlm.nih.gov/articles/PMC8448270/
